Advertisement
Amgen Inc.

Amgen Inc. (4332.HK) Stock Competitors & Peer Comparison

See (4332.HK) competitors and their performances in Stock Market.

4332.HKHKSE
HealthcareBiotechnology
HK$1850.00
HK$0.00(0.00%)
Hong Kong Market opens in 40h 57m
Advertisement

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
4332.HKHK$1,850.00+0.00%998.5B16.70HK$110.75N/A
6160.HKHK$165.90-0.66%223.8B75.00HK$2.21N/A
2269.HKHK$33.04-0.18%136.9B25.85HK$1.28N/A
1801.HKHK$75.15-1.25%130.4B138.19HK$0.54N/A
6990.HKHK$418.00+1.31%97.5B-207.23-HK$2.02N/A
9926.HKHK$83.30-2.52%76.6B-62.10-HK$1.34N/A
3347.HKHK$33.98+3.35%41.2B34.78HK$0.98+0.43%
6821.HKHK$111.30+2.58%40.2B36.49HK$3.05+1.34%
1530.HKHK$15.91-0.93%39.8B4.14HK$3.84+1.57%
2696.HKHK$55.50-6.49%30.2B22.37HK$2.48N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

4332.HK vs 6160.HK Comparison June 2026

4332.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 4332.HK stands at 998.5B. In comparison, 6160.HK has a market cap of 223.8B. Regarding current trading prices, 4332.HK is priced at HK$1,850.00, while 6160.HK trades at HK$165.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

4332.HK currently has a P/E ratio of 16.70, whereas 6160.HK's P/E ratio is 75.00. In terms of profitability, 4332.HK's ROE is N/A, compared to 6160.HK's ROE of +0.12%. Regarding short-term risk, 4332.HK is less volatile compared to 6160.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 4332.HK.Check 6160.HK's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions